Acumen Pharmaceuticals, Inc. (ABOS)
NASDAQ
Delayed Data
Oct 23, 2026, 01:30 PM
Day's Range
1.9052 wk Range
1.50Overview - ABOS - Acumen Pharmaceuticals, Inc.
Key Statistics
Valuation
Enterprise Value
76.20M
P/E (Trailing)
-1.00
P/E (Forward)
-1.49
PEG Ratio
0.02
Price / Book
2.70
EV / EBITDA
-0.72
Profitability
Profit Margin
0.00%
Operating Margin
0.00%
Return on Assets
-45.76%
Return on Equity
-120.50%
Ownership
Shares Outstanding
72.31M
Float
37.04M
Short % of Shares Outstanding
6.11%
Held by Insiders
6.79%
Held by Institutions
66.59%
Price stats
Beta
0.33
50-Day Avg
2.60
200-Day Avg
2.51
Dividends
Payout Ratio
0.00%
Analyst Consensus
6 analysts
Average price target
$ 7.60Shariah Compliance
Report Date: Feb 17, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - ABOS - Acumen Pharmaceuticals, Inc.
Peers - ABOS - Acumen Pharmaceuticals, Inc.
Peer Comparison
Compared with companies in Biotechnology listed on NASDAQ.
- ABOSNASDAQAcumen Pharmaceuticals, Inc.146.08MMarket Cap-15.35%52-week change-1.01P/E (Trailing)0.00%Profit Margin
- ARGXNASDAQArgenx SE51.51BMarket Cap-3.70%52-week change31.22P/E (Trailing)32.26%Profit Margin
- ALNYNASDAQAlnylam Pharmaceuticals, Inc.31.02BMarket Cap-111.89%52-week change39.09P/E (Trailing)16.12%Profit Margin
- BNTXNASDAQBioNTech SE American Depositary Share22.13BMarket Cap-20.35%52-week change160.80P/E (Trailing)-63.63%Profit Margin
- ASNDNASDAQAscendis Pharma A/S16.01BMarket Cap+16.49%52-week change18.23P/E (Trailing)70.84%Profit Margin
- BBIONASDAQBridgeBio Pharma Inc.12.97BMarket Cap+15.27%52-week change-17.56P/E (Trailing)-97.02%Profit Margin
- BMRNNASDAQBioMarin Pharmaceutical Inc.10.58BMarket Cap+1.57%52-week change147.76P/E (Trailing)2.14%Profit Margin
Profile Summary - ABOS - Acumen Pharmaceuticals, Inc.
About
Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for Alzheimer’s disease. The company’s lead program centers on sabirnetug (ACU193), an investigational immunotherapy designed to selectively target toxic soluble amyloid beta oligomers, which are…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
